Astrazeneca PLC Sponsored ADR (AZN.US) monoclonal antibody new drug for two indications listed in China.

On August 17, Astrazeneca PLC Sponsored ADR (AZN.US) announced the official launch of Tezspire (tezepelumab) injection in China. Tezspire is a biologic therapy that treats severe asthma and overcomes the limitations of phenotype and biomarker levels, targeting thymic stromal lymphopoietin (TSLP). In March 2026, Tezspire received approval in China for two indications based on positive results from the DIRECTION and WAYPOINT phase 3 clinical studies: for the maintenance treatment of severe asthma in adults and adolescents aged 12 years and older; and in combination with intranasal corticosteroids for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) where systemic corticosteroids and/or surgery are insufficient to control the disease. Tezspire is a human monoclonal antibody developed in collaboration between Astrazeneca PLC Sponsored ADR and Amgen, which inhibits the activity of TSLP. TSLP is a key epithelial cell cytokine located upstream of multiple inflammatory cascades and plays a central role in initiating and sustaining allergic, eosinophilic, and epithelial-driven inflammation associated with severe asthma, chronic rhinosinusitis with nasal polyps, and other inflammatory diseases.